© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 4, 321-328,
February 16, 2000
© 2000 Oxford University Press
REPORTS |
Randomized Clinical Trial of Adenosine 5'-Triphosphate in Patients With Advanced Non-Small-Cell Lung Cancer
Affiliations of authors: H. J. Agteresch, J. H. P. Wilson (Department of Internal Medicine), T. Stijnen (Epidemiology and Biostatistics), Erasmus University Medical Center Rotterdam, The Netherlands; P. C. Dagnelie, Department of Epidemiology, Maastricht University, The Netherlands, and Department of Internal Medicine, Erasmus University Medical Center Rotterdam; A. van der Gaast, Department of Medical Oncology, Rotterdam Cancer Institute—Dr. Daniel den Hoed Cancer Center and University Hospital Rotterdam—Dijkzigt.
Correspondence to: Pieter C. Dagnelie, Ph.D., Department of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands (e-mail: dagnelie{at}epid.unimaas.nl ).
BACKGROUND: Extracellular adenosine 5'-triphosphate (ATP) is involved in the regulation of a variety of biologic processes, including neurotransmission, muscle contraction, and liver glucose metabolism, via purinergic receptors. In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status. We conducted a randomized clinical trial to evaluate the effects of ATP in patients with advanced NSCLC (stage IIIB or IV). METHODS: Fifty-eight patients were randomly assigned to receive either 10 intravenous 30-hour ATP infusions, with the infusions given at 2- to 4-week intervals, or no ATP. Outcome parameters were assessed every 4 weeks until 28 weeks. Between-group differences were tested for statistical significance by use of repeated-measures analysis, and reported P values are two-sided. RESULTS: Twenty-eight patients were allocated to receive ATP treatment and 30 received no ATP. Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P = .002). Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P = .006). Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1.4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P = .01). A similar pattern was observed for knee extensor muscles (P = .02). The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P = .0002, P = .0001, and P = .0001, respectively, for ATP versus no ATP). QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group—physical scores (-0.2% versus -2.4%; P = .0002); functional scores (+0.4% versus -5.5%; P = .02); psychologic scores (-0.7% versus -2.4%; P = .11); overall QOL score (+0.1% versus -3.5%; P = .0001). CONCLUSIONS: This randomized trial demonstrates that ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. A. Kolosova, T. Mirzapoiazova, L. Moreno-Vinasco, S. Sammani, J. G. N. Garcia, and A. D. Verin Protective effect of purinergic agonist ATP{gamma}S against acute lung injury Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L319 - L324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Radbruch, F. Strasser, F. Elsner, J. F. Goncalves, J. Loge, S. Kaasa, F. Nauck, P. Stone, and the Research Steering Committee of the European As Fatigue in palliative care patients -- an EAPC approach Palliative Medicine, January 1, 2008; 22(1): 13 - 32. [Abstract] [PDF]
|
|
|
|
 |
|
 J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow Mechanisms of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 22 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sood, D. L. Barton, B. A. Bauer, and C. L. Loprinzi A Critical Review of Complementary Therapies for Cancer-Related Fatigue Integr Cancer Ther, March 1, 2007; 6(1): 8 - 13. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Yin, K. Xu, J. Zhang, A. Kumar, and F.-S. X. Yu Wound-induced ATP release and EGF receptor activation in epithelial cells J. Cell Sci., March 1, 2007; 120(5): 815 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yennurajalingam and E. Bruera Palliative Management of Fatigue at the Close of Life: "It Feels Like My Body Is Just Worn Out" JAMA, January 17, 2007; 297(3): 295 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Tisdale Clinical Anticachexia Treatments Nutr Clin Pract, April 1, 2006; 21(2): 168 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Burnstock Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev., March 1, 2006; 58(1): 58 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Earle Outcomes Research in Lung Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 56 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jatoi and C. L. Loprinzi Adenosine Triphosphate: Does It Help Cancer Patients "Get Bigger and Stronger"? J. Clin. Oncol., January 15, 2002; 20(2): 362 - 363. [Full Text] [PDF]
|
|
|
|
|
|
H. J. Agteresch, T. Rietveld, L. G.M. Kerkhofs, J. W. O. van den Berg, J. H. P. Wilson, and P. C. Dagnelie Beneficial Effects of Adenosine Triphosphate on Nutritional Status in Advanced Lung Cancer Patients: A Randomized Clinical Trial J. Clin. Oncol., January 15, 2002; 20(2): 371 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jatoi, B. D.T. Daly, V. A. Hughes, G. E. Dallal, J. Kehayias, and R. Roubenoff Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann. Thorac. Surg., August 1, 2001; 72(2): 348 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Burnstock and M. Williams P2 Purinergic Receptors: Modulation of Cell Function and Therapeutic Potential J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 862 - 869. [Full Text]
|
|
|
|
 |
|
 A. Jatoi, C. L. Loprinzi, J. Sloan, and R. M. Goldberg Is ATP (Adenosine 5'-Triphosphate), like STP(R), a Performance-Enhancing Additive for the Tanks of Cancer Patients? J Natl Cancer Inst, February 16, 2000; 92(4): 290 - 291. [Full Text] [PDF]
|
|